Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial. Issue 2 (February 2023) - Wang, Guiqiang; Zhao, Kexin; Han, Jun; Hu, Zhongyu; Zhang, Tianzuo; Wang, Yanchao; Shi, Rui; Li, Yanhua; Song, Qinqin; Du, Haijun; He, Peng; Xu, Shuping; et al.